# Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease

Study · id `cardio:ct-nct07625774` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07625774](<https://clinicaltrials.gov/study/NCT07625774>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07625774

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 3690 participants.

## Technical summary

Registry record NCT07625774. Randomized; quadruple masking; primary purpose treatment. Start 2026-07 (anticipated); primary completion 2031-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 3690 participants (planned count; ClinicalTrials.gov record NCT07625774, source copy `cardio:ctgov-nct07625774-2026-06-04`, retrieved 2026-10-26)
- Planned start: 2026-07 (anticipated) (ClinicalTrials.gov record NCT07625774, source copy `cardio:ctgov-nct07625774-2026-06-04`, retrieved 2026-10-26)
- Primary completion: 2031-05 (anticipated) (ClinicalTrials.gov record NCT07625774, source copy `cardio:ctgov-nct07625774-2026-06-04`, retrieved 2026-10-26)
- Completion: 2031-07 (anticipated) (ClinicalTrials.gov record NCT07625774, source copy `cardio:ctgov-nct07625774-2026-06-04`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07625774, source copy `cardio:ctgov-nct07625774-2026-06-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07625774-2026-06-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease
- Acronym: RENEW-CKD
- Condition: Chronic Kidney Disease
- Intervention (Drug): HRS-7535
- Intervention (Drug): Placebo
- Lead sponsor: Shandong Suncadia Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Shandong Suncadia Medicine Co., Ltd. (`cardio:org-shandong-suncadia-medicine-co-ltd`)

## Provenance

Content hash: a0bc837ad800cfebff128982094d748c28d38a0543c97342ade31202d4f08f69
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
